title: Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy.
abstract: For the past century, subcutaneous allergen-specific immunotherapy has been the state-of-the-art treatment for IgE-mediated allergic disease. Current research on allergen-specific immunotherapy is focused on enhancing its efficacy, safety, and patient convenience with the goal of offering a broadly accepted treatment option. There is a growing interest in intralymphatic allergen-specific immunotherapy because it is a highly efficacious and safe treatment route that requires only 3 injections. Concurrently, epicutaneous allergen-specific immunotherapy is attracting increasing attention because of its capacity to offer a safe, needle-free, and potentially self-administrable treatment option for IgE-mediated allergic diseases. In this article, we discuss the principles and immunologic rationale of these unconventional routes of allergen-specific immunotherapy while highlighting their developmental process and clinical relevance.
authors.affiliation: Clinical Trials Center, Center for Clinical Research, University and University Hospital Zürich, Moussonstrasse 2, 8091 Zürich, Switzerland.
authors.forename: Seraina
authors.initials: S
authors.lastname: von Moos
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Kündig
authors.forename: Gabriela
authors.initials: G
authors.lastname: Senti
mesh_terms: D000485:Allergens / Q000276:immunology / Q000627:therapeutic use*; D000818:Animals; D003888:Desensitization, Immunologic; D004333:Drug Administration Routes; D006801:Humans; D007272:Injections, Intralymphatic; D012867:Skin / Q000276:immunology
chemical_list: D000485:Allergens